Medicare Covers Ultrasensitive MRD Test for Breast Cancer Surveillance
Coverage applies to stage II and III breast cancer patients across three major subtypes for up to six years of recurrence monitoring.
Coverage applies to stage II and III breast cancer patients across three major subtypes for up to six years of recurrence monitoring.
A new peer-reviewed study confirms that Ibex Breast significantly enhances accuracy, speed, and efficiency of breast pathology evaluations.
Ibex has introduced advancements to its AI-powered platform, enhancing breast cancer diagnostics, improving algorithm accuracy, and more.
The AidaBreast novel biosignature also predicts radiation therapy benefit for early-stage invasive breast cancer patients.
Read MoreFor patients with metastatic HR+ breast cancer, there may be no test more important than monitoring for an ESR1 mutation.
Read MoreScientists developed a saliva test that screens for breast cancer, which is showing promising results in experimental testing.
Read MoreThe commonly ordered biomarker test is used to guide doctor’s recommendations for patients with estrogen receptor-positive breast cancer.
Read MoreA new test uses AI to see whether a patient is positive for cancer as soon as detectable by mammogram or earlier, and before symptoms arise.
Read MoreThough breast cancer rates for men are much lower, it is estimated that in 2023, about 2,800 men will be diagnosed with breast cancer.
Read MoreExai Bio’s liquid biopsy platform can detect breast cancer at the earliest stages and the smallest tumor sizes using a standard blood sample.Â
Read MoreDNADX utilizes sequencing DNA data from tumor tissue or plasma circulating tumor DNA to classify breast cancer into four subtypes or clusters.
Read MorePreciseBreast, an AI-powered digital morphology tool, has a fast turnaround time and is cost-effective compared to gene expression tests.
Read MoreInvitae announced the results of its study on universal hereditary cancer genetic testing in breast cancer patients in a rural population.
Read MoreBiocartis and APIS Assay Technologies are expanding their collaboration to include the commercialization of the APIS ESR1 Mutations Kit.
Read MoreThe findings suggest the need for continued monitoring of access to breast cancer screening and early diagnosis services.
Read MoreIbex launched an AI-powered solution that aids pathologists in setting a higher standard for accurate HER2 scoring in breast cancer patients.
Read MoreThis computational model makes it possible to predict the genetic risk of developing breast cancer based on genetic profiles.Â
Read MoreNew findings suggest that overdiagnosis may be common among older women who are diagnosed with breast cancer after screening.
Read More